PATENT CLAIM ANALYSIS

Application Number: 16084668
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["424", "450000"]

Abstract:
Disclosed is an Edaravone dosage form and a use thereof in preparing a drug used for treating diseases related to oxidative stress, the dosage form being selected from a lipid-based delivery system, a solid dispersion, micelles and a co-solvent based formulation.

Claim (Index 1):
A lipid-based drug delivery system comprising Edaravone or its pharmaceutically acceptable salt thereof as an active ingredient, and a lipid, wherein the lipid is a triglyceride, including a long chain triglyceride (LCT), a medium chain triglyceride (MCT) and a short chain triglyceride (SCT), wherein the long-chain triglyceride is selected from the group consisting of hydrogenated soybean oil, hydrogenated vegetable oil, corn oil, olive oil, soybean oil, peanut oil, and sesame oil, and the medium chain triglyceride is selected from the group consisting of caprylic/capric triglyceride derived from coconut oil or palm seed oil.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 97.0
- Lexical Diversity: 1.25
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15844365', '13884182', '12876292', '13707122', '13414369']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.71272828028853
- 35 USC 102 Novelty (BERT): 0.502078010444478
- Combined Prediction Score: 0.6916632533041248
- Mean Citation Score: 214.404466
- Max Citation Score: 254.98409
- Similarity Product: 180.5220647886217

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test